Ramy Ibrahim, MD, is a recognised leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Meyer Squibb and MedImmune/AstraZeneca.
At AstraZeneca, Dr. Ibrahim was the vice president of clinical development for Immuno-Oncology, leading the team developing multiple immunotherapies. Molecules developed under his leadership included durvalumab (anti-PDL1 antibody) and tremelimumab (anti-CTLA4 antibody) both with single drug and combination therapies with a focus on registrational studies in multiple indications including lung cancer, bladder cancer and head and neck cancer.
As a member of the Bristol Meyers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PDL1, and CD137 antibody.
Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as Society of Immunotherapy for Cancer (SITC), Ludwig Institute, and the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch, National Cancer Institute in Bethesda, MD. Dr. Ibrahim currently serves as Vice President, Clinical Development at the Parker Institute